IMUX - Immunic, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

IMUX

IMMUNIC, INC.

NASDAQ

$15.40

▼ DOWN 5.52% (-0.90)

KEY STATISTICS

Market Cap$209.77 M

52w High$17.43

52w Low$5.06

Dividend Yield—

Frequency—

P/E-5.90

Volume357.90K

Shares Out.13.62M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Erik Lundgren

COMPENSATION 2026

Salary$625,250

Stock Awards$0

Incentive Plan Pay$401,258

All Other Comp.$100,000

Total$2,302,889

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 17, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$45.00

Target Low$2.50

Target Median$20.50

Target Consensus$22.13

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-04-27	Reverse	1:10
2019-04-15	Reverse	1:40

PRICE

$15.40 ▼ DOWN 5.52% (−$0.90)

OVERLAYS

About Immunic, Inc.

https://imux.com ↗

Immunic, Inc. is a NY-based clinical-stage biopharma developing oral immunology therapies, including IMU-838 for multiple sclerosis and inflammatory diseases, and IMU-856 to restore intestinal barrier function.

INDUSTRY

Biotechnology

A PRODUCT IMMUNIC, INC. IS KNOWN FOR

Vidofludimus calcium (IMU-838)

Vidofludimus calcium, Immunic's lead Phase 3 oral therapy for relapsing multiple sclerosis, is their primary focus in developing innovative treatments for chronic inflammatory and autoimmune diseases.